Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AH69593 in Healthy Participants and Participants With Narcolepsy
NCT07613710Phase 1Recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AH69593 in narcolepsy (4 arms), sponsored by Lundbeck. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Day 90, Bond Lader Visual Analogue Scale dimension scores at Day 84 and 8 more. Started Jun 2025; status: recruiting.
02
Drugs
Lu AH69593
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT07613710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613710.